S
Suzhou Zhihe Biomedical Technology
Making imaging agents for pd-l1 and cd8+ t cells
About Suzhou Zhihe Biomedical Technology
SmartNuclide Biopharma is pioneering the development of innovative nuclear medicine treatments, focusing on targeted therapies that offer new hope to patients with cancer. Established in 2015 and located in Suzhou Industrial Park, the company is committed to leveraging cutting-edge technologies to develop diagnostic and therapeutic solutions that address unmet medical needs in oncology.
SmartNuclide’s primary innovation lies in its SRC (Single-domain Radiopharmaceuticals for Cancer) technology platform, which integrates single-domain antibodies with radionuclide technology to create novel biomolecular agents. These agents are designed to target specific cancer-related biomarkers, allowing for precise imaging and treatment of various cancer types.
The company's product pipeline includes several promising candidates:
SNA001: A recombinant human thyroid-stimulating hormone (rhTSH), enhances radioiodine therapy's efficacy in differentiated thyroid cancer, reducing treatment discomfort.
SNA002: A radiolabeled imaging agent targeting PD-L1, which is crucial for the non-invasive assessment of tumor PD-L1 expression and monitoring immunotherapy efficacy.
SNA006: A CD8+ T-cell imaging agent, offering insights into the immune system's activity within the tumor microenvironment, crucial for evaluating immunotherapeutic interventions.
SNA018: Details are less specified, but like its peers, it is aimed at enhancing the diagnosis and treatment of oncological diseases.
SmartNuclide is also recognized for its contribution to the scientific community, with multiple research papers published in esteemed journals, adding valuable knowledge to the field of nuclear medicine.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Apr 2024 | $14M | $55M | Guangzhou Jiansu Private Equity Fund · Oriza Holdings · Leading Venture Capital · Realharmony Capital | ↗ |
| SERIES B✓Equity / VC | Apr 2020 | $14M | $56M | Ruihe Investment | ↗ |
Growth signals
Latest recorded traffic for Suzhou Zhihe Biomedical Technology is 330 monthly website visits, down 35.3% over the last three months. Suzhou Zhihe Biomedical Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Zhihe Biomedical Technology in the Suzhou Shi ecosystem
The Suzhou Zhihe Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- AOAlphamab Oncology
Series A2 investors entered at this stage
- LCLongmen Capital
- RIRuihe Investment
Series B and later5 investors entered at this stage
- GFGuangzhou Jiansu Private Equity Fund
Oriza Holdings- LCLeading Venture Capital
- RCRealharmony Capital
- YCYuzhi Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Zhihe Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Zhihe Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










